BioSpace News Archive

Drug Development

Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting

The oral presentation of data from 33 patients treated within 9 cohorts demonstrated that AMV564 is active in relapsed or refractory AML and expanded upon the data from 26 patients presented at the Annual Meeting of the American Society of Hematology in December 2018.

July 1, 2019
·
3 min read
Business

Top Healthcare Leader Jack Cox, MD, MMM, Joins THEO Executive Group As Senior Advisor

National expert in healthcare’s transformation joins a renowned group advising top executives

July 1, 2019
·
3 min read
Deals

Celling Spine Acquires Assets of Link Spine to Further Develop and Promote a Cell Centric Spine Platform

Celling believes this technology compliments the current portfolio and supports the development of a biologically enhanced spinal fusion system.

July 1, 2019
·
3 min read
Global Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023 | Development of Gene Therapy for AMD Devices to Boost Growth | Technavio

The global age-related macular degeneration (AMD) therapeutics market is expected to post a CAGR close to 8% during the period 2019-2023, according to the latest market research report by Technavio

July 1, 2019
·
4 min read
Business

Mobidiag Signs Exclusive Agreement With Pro Med Diagnostics for the Distribution of Amplidiag® and Novodiag® Diagnostic Solutions in Africa

Agreement signed for South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, Uganda

July 1, 2019
·
2 min read
MeMed Named “Technology Pioneer” by World Economic Forum

Company Recognized for Novel Solution to Combat Growing Threat of Antibiotic Resistance

July 1, 2019
·
5 min read
Deals

Merck to Hold Second-Quarter 2019 Sales and Earnings Conference Call on July 30

Merck, known as MSD outside the United States and Canada, will hold its second-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 30.

July 1, 2019
·
3 min read
Deals

NovaBay Pharmaceuticals Plan of Compliance Accepted by NYSE

NovaBay® Pharmaceuticals, Inc., a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that the New York Stock Exchange has accepted the Company’s plan to regain compliance with the NYSE American’s continued listing standards.

July 1, 2019
·
3 min read
Business

Viela Bio Appoints Mitchell Chan as Chief Financial Officer

Viela Bio announced the appointment of Mitchell Chan as Chief Financial Officer, effective July 1.

July 1, 2019
·
2 min read
Deals

Miraca and Seventh Sense Biosystems, Inc. Announce Strategic Investment and Distribution Agreement

Seventh Sense Biosystems, Inc., makers of TAP™, the world’s first push-button blood collection device, and Miraca Holdings Inc.

July 1, 2019
·
2 min read